Company profile
Beijing Biotech
Privately held: no public share price
Assets
(5 total)
5Total Assets
0Approved
0Phase 3 / Filed
5Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | CD19Cell therapy | Systemic Lupus Erythematosus | |
| Phase 1/2 | BCMA × CD19Cell therapy | Multiple Myeloma | |
| Phase 1/2 | BCMA, CD38 (dual-target)Cell therapy | Multiple Myeloma | |
| Phase 1/2 | BCMA / GPRC5DCell therapy | Multiple Myeloma | |
| Phase 1/2 | Dual-antigen combinations: MSLN+EGFR, MSLN+HER2/ERBB2Cell therapy | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.